UNASSIGNED: The study included 120 patients with LUTS symptoms caused by prostatic enlargement of more than 80 ml; 79 patients were treated with SP, while 41 were treated with PVP. The analysis included subjective the International Prostate Symptom Score (IPSS) and Quality of Life (QoL), and objective (Qmax), (Qave), and post-void residual volume (PVR) parameters before treatment and at an average of 38 months after surgical treatment. Early and late adverse effects and length of hospitalisation were assessed. Complication reports were performed according to the modified Clavien-Dindo system.
UNASSIGNED: The analysis independently showed the effectiveness of both methods. Subjective parameters (IPSS, QoL), showed no significant differences. Patients treated with SP scored slightly better on objective parameters (Qmax, Qave, and PVR). Analysis of adverse effects and hospitalisation time were more favourable after PVP.
UNASSIGNED: SP and PVP were found to be comparable and highly effective in treating benign prostatic hyperplasia in terms of IPSS and QoL. Patients treated with the SP method obtained slightly better results of objective parameters such as Qmax, Qave, and PVR. Compared with SP, PVP has a more favourable safety profile.
■该研究包括120例前列腺肿大引起的LUTS症状超过80毫升的患者;79例患者接受了SP治疗,而用PVP治疗41例。分析包括主观的国际前列腺症状评分(IPSS)和生活质量(QoL),和目标(Qmax),(Qave),治疗前和手术治疗后平均38个月的空隙残余体积(PVR)参数。评估早期和晚期不良反应以及住院时间。根据改良的Clavien-Dindo系统进行并发症报告。
■分析独立地显示了两种方法的有效性。主观参数(IPSS,QoL),没有显著差异。接受SP治疗的患者在客观参数上得分略好(Qmax,Qave,和PVR)。PVP术后不良反应和住院时间分析更为有利。
■在IPSS和QoL方面,SP和PVP在治疗良性前列腺增生方面具有可比性,并且非常有效。使用SP方法治疗的患者获得了较好的客观参数结果,例如Qmax,Qave,PVR。与SP相比,PVP具有更有利的安全性。